Skip to content
HCN Grants Est. 2026
No. HT942526BMFRPRDA · Defense Health Agency Contracting Activity - DHACA
Open

DoW Bone Marrow Failure, Resource Development Award

Dealbreakers No cost share required Audit: not stated Reimbursement-only: not stated

At a glance

The FY26 Bone Marrow Failure Research Program Resource Development Award funds development of a multiomic atlas from well-annotated human bone marrow failure samples, with an open-access data resource for researchers, clinicians, and the public. Eligible applicants include U.S. Department of War organizations and domestic or foreign, for-profit or nonprofit, public or private entities, and principal investigators at all career levels may apply if affiliated with an eligible organization. The program expects to fund about one award, with total costs capped at $1.25 million and a maximum project period of 2 years. Cost sharing is not required. The award is for bone marrow failure research only, does not allow clinical trials or animal study costs, and focuses on durable resources for the bone marrow failure research community.

AI-generated summary — verify against the announcement

What it funds

  • Science and Technology and other Research and Development
  • Infrastructure, Construction & Shared Facilities
  • Research & Discovery
  • Researchers & Scholars
  • Biomedical & Disease Research
  • Research Infrastructure, Instrumentation & Data
Official description from grants.gov

Summary: The fiscal year 2026 (FY26) Bone Marrow Failure Research Program (BMFRP) Resource Development Award (RDA) supports the development of a multiomic atlas generated from well-annotated human bone marrow failure (BMF) samples, with omic data derived from marrow specimens. The resulting dataset should serve as an open-access, durable resource for the BMF research and clinical communities and is expected to facilitate key discoveries that advance the understanding of BMF diseases. Distinctive Features: The application must include a robust Data Resource Sharing Plan that describes the means and timeline by which the fully developed resource will be made available to the scientific and clinical community.

Who can apply

  • Unrestricted
Geographic restriction None found in the announcement — likely nationwide